Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 110.8 mg (equivalent: vinorelbine, qty 80 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: vinorelbine pierre fabre is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 41.55 mg (equivalent: vinorelbine, qty 30 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide red; titanium dioxide; medium chain triglycerides; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: vinorelbine pierre fabre is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - vinorelbine tartrate, quantity: 41.55 mg (equivalent: vinorelbine, qty 30 mg) - capsule, soft - excipient ingredients: polysorbate 80; titanium dioxide; iron oxide red; purified water; macrogol 400; partially dehydrated liquid sorbitol; gelatin - non-small cell lung cancer: vinorelbine lrx is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination. ,breast cancer: vinorelbine lrx is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - vinorelbine tartrate, quantity: 41.55 mg (equivalent: vinorelbine, qty 30 mg) - capsule, soft - excipient ingredients: gelatin; iron oxide red; partially dehydrated liquid sorbitol; titanium dioxide; macrogol 400; purified water; polysorbate 80 - non-small cell lung cancer: vinorelbine lu is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination. ,breast cancer: vinorelbine lu is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - vinorelbine tartrate, quantity: 110.8 mg (equivalent: vinorelbine, qty 80 mg) - capsule, soft - excipient ingredients: iron oxide yellow; partially dehydrated liquid sorbitol; gelatin; polysorbate 80; macrogol 400; purified water; titanium dioxide - non-small cell lung cancer: vinorelbine lrx is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination. ,breast cancer: vinorelbine lrx is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - vinorelbine tartrate, quantity: 110.8 mg (equivalent: vinorelbine, qty 80 mg) - capsule, soft - excipient ingredients: purified water; macrogol 400; polysorbate 80; gelatin; titanium dioxide; iron oxide yellow; partially dehydrated liquid sorbitol - non-small cell lung cancer: vinorelbine lu is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination. ,breast cancer: vinorelbine lu is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Canada - English - Health Canada

agila jamp canada inc - vinorelbine (vinorelbine tartrate) - solution - 10mg - vinorelbine (vinorelbine tartrate) 10mg - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

flynn pharma ltd - vinorelbine tartrate - concentrate for soln for inf - 10 base mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vinorelbine tartrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vinorelbine tartrate -